Themis Medicare Limited (NSE: THEMISMED) announced its financial results for the period ended March 31, 2026, following a Board meeting held on May 28, 2026. While the company has not separately filed a dividend announcement for FY2026 in the current exchange disclosure, its results submission follows a consistent pattern where the board has recommended a final dividend of ₹0.50 per equity share in each of the past two fiscal years, FY2024 and FY2025, establishing a clearly defined payout floor.

Dividend Details and Yield

The final dividend of ₹0.50 per equity share on shares with a face value of ₹10 represents a payout rate of 5% on face value. With exchange trade data currently unavailable for THEMISMED, a precise trailing dividend yield cannot be computed at this time. Investors should calculate the yield by dividing ₹0.50 by the prevailing market price to assess income return relative to current valuations.

Historical Dividend Trend

A review of Themis Medicare's dividend history over nearly two decades reveals a pronounced downward trajectory in per-share payouts:

The sharp compression from ₹4.30 in FY2021 to ₹0.50 in FY2024 and FY2025 marks an 88.4% reduction in absolute dividend per share over just three years. The stabilisation at ₹0.50 across FY2024 and FY2025 suggests the company has found a near-term payout equilibrium, though the level remains substantially below its FY2021 peak. Investors tracking income generation from this stock should note that the current payout represents the lowest absolute dividend in over 15 years of recorded history.

Company Background

Themis Medicare Limited is a pharmaceutical manufacturer listed on the NSE with ISIN INE083B01016. The company operates in the Indian pharma space and has been a listed entity for over two decades. Its product portfolio spans active pharmaceutical ingredients and formulations, serving both domestic and export markets.

Market Context and What It Means for Investors

The absence of live quote and trade information in the current data set limits a full assessment of delivery percentage significance and 52-week range context. These metrics, which typically indicate institutional conviction and price momentum, should be independently verified on the NSE platform before drawing conclusions about near-term investor sentiment.

The flat dividend at ₹0.50 for a second consecutive year signals management's preference to conserve capital rather than scale distributions, a posture that income-focused investors in the mid-cap pharma segment should weigh carefully. Companies in the Indian pharmaceutical sector have broadly prioritised reinvestment in research, regulatory compliance, and capacity expansion over elevated dividend payouts in recent years, and Themis Medicare's trajectory appears consistent with that broader sectoral pattern.

Investors are advised to review the detailed financial results filed by the company for FY2026, including revenue, EBITDA margins, and debt levels, to form a complete picture of the company's capacity to sustain or grow its dividend in subsequent years.